vTv Therapeutics Inc. has announced the reinitiation of its CATT1 Phase 3 clinical trial for cadisegliatin, an investigational oral adjunctive therapy to insulin for the treatment of type 1 diabetes. This development follows the company's appointment of Michael Tung, M.D., MBA, as the new Chief Financial Officer. Dr. Tung brings over 20 years of experience in finance and strategic leadership within the biopharmaceutical industry. The trial aims to further explore cadisegliatin's potential as a first-in-class therapy to enhance diabetes management. This initiative represents a key step forward in vTv Therapeutics' efforts to advance its pipeline and achieve its strategic objectives in the field of diabetes treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.